Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Amgen Inc. (AMGN) — XLV Health Care · S&P 500 Profile |安進公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Amgen Inc. (AMGN) — Business, History & S&P 500 Profile | 安進公司介紹

Amgen Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #48 · 安進公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 28, 2026 (ET) close
Financials: FY2024
MARKET CAP
$244.27B
Oct 28, 2026 close
S&P 500 WEIGHT
0.35%
Rank #48 · Oct 28, 2026
SECTOR RANK
#7
Health Care · Oct 28, 2026
S&P 500 RANK
#48
0.35% · Oct 28, 2026

SNAPSHOT

TickerAMGN
CompanyAmgen Inc.
GICS sector / industryHealth Care (XLV) / Biotechnology
S&P 500 rank (by weight)#48 · 0.35% (Oct 28, 2026)
Sector rank#7 in Health Care (Oct 28, 2026)
HeadquartersThousand Oaks, California
Founded1980
CEORobert A. Bradway (Chairman and CEO since 2012)
EmployeesApproximately 28,000 (Dec 31, 2024)
Market cap$244.27B (Oct 30, 2026)
Share price$466.01 (Oct 30, 2026 close)
SEC filingsEDGAR — CIK 0000318154

WHAT IT DOES

Amgen is a biotechnology company. Its one-line model: discover, develop, manufacture and sell biologic and specialty medicines for serious illnesses.

Revenue comes from product sales through wholesalers, physicians, clinics, hospitals and pharmacies, led by a set of blockbuster medicines in bone health, cardiovascular disease, inflammation and oncology. Amgen manufactures much of its own product, unlike many biotech peers that outsource production.

The economics are patent- and pipeline-driven: a medicine's sales last while its patents hold, so research spending and new approvals must replace maturing products before biosimilars erode them.

BUSINESS SEGMENTS

Prolia & XgevaBone health medicines for osteoporosis and skeletal-related events in cancer. FY2024 product sales $6,599M.
RepathaCholesterol-lowering medicine for cardiovascular risk reduction. FY2024 product sales $2,222M.
EnbrelInflammatory disease medicine for rheumatoid arthritis, psoriasis and related conditions. FY2024 product sales $3,316M.
OtezlaOral medicine for psoriasis and psoriatic arthritis. FY2024 product sales $2,126M.
EvenityBone-building medicine for osteoporosis in postmenopausal women at high fracture risk. FY2024 product sales $1,563M.
TezspireSevere asthma medicine developed with AstraZeneca. FY2024 product sales $972M.
BlincytoBlood cancer medicine for acute lymphoblastic leukemia. FY2024 product sales $1,216M.
Amgen reports one operating segment; revenue is shown here by product franchise.

HISTORY

YearMilestone
1980Amgen is founded in Thousand Oaks, California.
2012Robert A. Bradway becomes chairman and chief executive officer.
2024Amgen reports record total revenues of $33.4 billion for 2024, with 14 blockbuster products.

COMPETITIVE POSITION

  • Manufacturing depth: in-house biologics production is a barrier that many smaller biotech firms cannot match.
  • A broad portfolio of 14 blockbuster products, so no single medicine decides the company's fate.
  • Pipeline breadth across oncology, cardiovascular disease, inflammation, bone health and rare diseases.
  • Competition set: AbbVie, Johnson & Johnson, Eli Lilly and Regeneron, each with large biologic franchises.
  • Biosimilar defense: patents, manufacturing know-how and new indications extend product lives.

FINANCIAL SNAPSHOT

Total revenue$36.75B (FY2025 total revenues)
Operating income$9.08B (FY2025 operating income)
Net income$7.71B (FY2025 net income)
Diluted EPS$14.23 (FY2025 diluted EPS)
Source: Amgen Q4 and full-year 2025 results release and 2025 shareholder letter (total revenues $36.75B; operating income $9.08B; net income $7.71B; diluted EPS $14.23).

KEY RISKS

  • Biosimilar competition that erodes sales of maturing blockbuster medicines.
  • Clinical trial failures or regulatory delays in the pipeline.
  • Pricing pressure from payers, governments and pharmacy benefit managers.
  • Manufacturing complexity for biologics, including quality and supply disruptions.
  • Concentration in a few large products despite portfolio breadth.

WHY IT MATTERS FOR THE S&P 500

Amgen is a mid-weight health care constituent: rank #48 by weight at 0.35% as of Oct 28, 2026, and #7 in Health Care. Its product sales and pipeline results are read as a gauge of biotechnology demand, and through it of innovation returns across the sector.

SOURCES & METHODOLOGY

Financials, segments, headquartersAmgen Q4 and full-year 2024 results release and 2024 shareholder letter
Index weight & ranksSlickcharts S&P 500 weights, Oct 28, 2026 close, fetched Oct 29, 2026
Market cap$244.27B (Oct 30, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

AMGN

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號AMGN
公司Amgen(安進)
GICS 板塊/行業醫療保健(XLV)/生物科技
標普500排名(按權重)#48 · 0.35%(Oct 28, 2026)
板塊內排名醫療保健 #7(Oct 28, 2026)
總部美國加利福尼亞州千樽模斯
成立1980年
執行長Robert A. Bradway(自2012年起出任董事長兼執行長)
員工約 28,000 人(2024 年 12 月 31 日)
市值$244.27B(Oct 30, 2026)
股價$466.01(Oct 30, 2026 收盤)
SEC 申報EDGAR — CIK 0000318154

業務概覽

Amgen 是一家生物科技公司。其一句話商業模式是:發現、開發、製造與銷售用於嚴重疾病的生物藥物與專科藥物。

收入來自透過批發商、醫師、診所、醫院與藥局銷售的產品,由骨骼健康、心血管、發炎與腫瘤領域的一批重磅藥物帶動。與許多將生產外包的生物科技同業不同,Amgen 自行製造大部分產品。

這種經濟由專利與產品線驅動:藥物的銷售在專利有效期間持續,故研發支出與新藥批准必須在生物相似藥侵蝕之前替代成熟產品。

業務板塊

Prolia 與 Xgeva骨骼健康藥物,用於骨質疏騆與癌症相關骨骼事件。 2024 財年產品銷售額 65.99 億美元。
Repatha降脂固醇藥物,用於降低心血管風險。 2024 財年產品銷售額 22.22 億美元。
Enbrel發炎性疾病藥物,用於類風濕性關節炎、療癣及相關疾病。 2024 財年產品銷售額 33.16 億美元。
Otezla口服藥物,用於療癣及療癣性關節炎。 2024 財年產品銷售額 21.26 億美元。
Evenity骨骼生成藥物,用於高骨折風險的停經後骨質疏騆。 2024 財年產品銷售額 15.63 億美元。
Tezspire嚴重哮喘藥物,與 AstraZeneca 合作開發。 2024 財年產品銷售額 9.72 億美元。
Blincyto血液癌症藥物,用於急性淋巴樣白血病。 2024 財年產品銷售額 12.16 億美元。
Amgen 報告單一營運板塊;此以產品系列列示收入。

歷史沿革

年份里程碑
1980Amgen 於加利福尼亞州千樽模斯成立。
2012Robert A. Bradway 出任董事長兼執行長。
2024Amgen 報告 2024 年總收入創紀錄 $33.4B,擁有 14 個重磅產品。

競爭地位

  • 製造深度:自行生產生物藥物是許多較小生物科技公司無法匹敵的門檻。
  • 14 個重磅產品的廣泛組合,不會由單一藥物決定公司命運。
  • 腫瘤、心血管、發炎、骨骼健康與罕見疾病的產品線廣度。
  • 競爭集合:AbbVie、Johnson & Johnson、Eli Lilly 與 Regeneron,各家均擁有大型生物藥物系列。
  • 生物相似藥防禦:專利、製造技術與新適應症延長產品壽命。

財務快照

總收入$36.75B(FY2025 總收入)
營業利潤$9.08B(FY2025 營業利潤)
淨利潤$7.71B(FY2025 淨利潤)
稀釋 EPS$14.23(FY2025 稀釋 EPS)
來源:Amgen Q4 及 2025 年全年派績發佈及 2025 年股東信(總收入 367.5 億美元;營業利潤 90.8 億美元;淨利潤 77.1 億美元;稀釋 EPS 14.23 美元)。

主要風險

  • 生物相似藥競爭侵蝕成熟重磅藥物的銷售。
  • 產品線的臨床試驗失敗或監管延迟。
  • 付費方、政府與藥品福利管理機構的價格壓力。
  • 生物藥物製造的複雜性,包括品質與供應中斷。
  • 儘管產品組合廣泛,仍集中於少數大型產品。

對標普500的重要性

Amgen 是權重中等的醫療保健成分股:按權重排名 #48,權重 0.35%(以 Oct 28, 2026 為準),醫療保健板塊內排名 #7。其產品銷售與產品線派績被視為生物科技需求的指標,並由此反映整個板塊的創新報酬。

來源與方法

財務、板塊、總部Amgen Q4 及 2024 年全年派績發佈及 2024 年股東信
指數權重與排名Slickcharts S&P 500 權重,Oct 28, 2026 收盤,Oct 29, 2026 抓取
市值$244.27B(Oct 30, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

AMGN

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · AMGN
Data as of Oct 28, 2026 · Financials FY2024 (10-K) · Market data Oct 2026
Previous · International Business Machines Corporation (IBM) — XLK Information Technology · S&P 500 Profile |IBM 公司介紹Next · Wells Fargo & Company (WFC) — XLF Financials · S&P 500 Profile |富國銀行公司介紹

Entered 2026-10-29 17:29 · updated 2026-11-14 22:58 · rev 11